4.8 Article

Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile

期刊

NATURE
卷 517, 期 7533, 页码 205-U207

出版社

NATURE PORTFOLIO
DOI: 10.1038/nature13828

关键词

-

资金

  1. US National Institutes of Health (NIH) [RO1 AI42135, AI95706]
  2. Tow Foundation
  3. NIH Office of the Director [DP2OD008440]
  4. NCI [U54 CA148967]
  5. Lucille Castori Center for Microbes, Inflammation, and Cancer
  6. Medical Scientist Training Program grant from the National Institute of General Medical Sciences of the NIH [T32GM07739]

向作者/读者索取更多资源

The gastrointestinal tracts of mammals are colonized by hundreds of microbial species that contribute to health, including colonization resistance against intestinal pathogens(1). Many antibiotics destroy intestinal microbial communities and increase susceptibility to intestinal pathogens(2). Among these, Clostridium difficile, a major cause of antibiotic-induced diarrhoea, greatly increases morbidity and mortality in hospitalized patients(3). Which intestinal bacteria provide resistance to C. difficile infection and their in vivo inhibitory mechanisms remain unclear. Here we correlate loss of specific bacterial taxa with development of infection, by treating mice with different antibiotics that result in distinct microbiota changes and lead to varied susceptibility to C. difficile. Mathematical modelling augmented by analyses of the microbiota of hospitalized patients identifies resistance-associated bacteria common to mice and humans. Using these platforms, we determine that Clostridium scindens, a bile acid 7 alpha-dehydroxylating intestinal bacterium, is associated with resistance to C. difficile infection and, upon administration, enhances resistance to infection in a secondary bile acid dependent fashion. Using a workflow involving mouse models, clinical studies, metagenomic analyses, and mathematical modelling, we identify a probiotic candidate that corrects a clinically relevant microbiome deficiency. These findings have implications for the rational design of targeted antimicrobials as well as microbiome-based diagnostics and therapeutics for individuals at risk of C. difficile infection.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据